0000000000403222

AUTHOR

Yu-ning Wong

showing 3 related works from this author

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemother…

2017

Background: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. Methods: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible. Those with incomplete or miscoded data were excluded. Khorana scores were calculated based on the pretreatment data and categorized into high (≥3) or intermediate (1-2) VTE risk. Other patient-, tumor-, and therapy-related factor…

MaleUrologic Neoplasmsmedicine.medical_specialtyMetastatic Urothelial Carcinomamedicine.medical_treatmentvenous thromboembolismAntineoplastic AgentsKhorana score030204 cardiovascular system & hematologyUrologic NeoplasmschemotherapyGastroenterologyArticleLeukocyte Count03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPredictive Value of TestsRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesLeukocytosisNeoplasm MetastasisAgedRetrospective StudiesChemotherapyBladder cancerbusiness.industryCancerRetrospective cohort studyHematologyGeneral MedicineMiddle Agedequipment and suppliesmedicine.disease3. Good healthSurgeryleukocytosisCardiovascular Diseases030220 oncology & carcinogenesisPredictive value of testsbladder cancerFemaleUrotheliummedicine.symptombusinessClinical and Applied Thrombosis/Hemostasis
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer

2016

Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC. Methods: Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3,024 consecutive patients from 29 international acade…

Research ReportOncologymedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologychemoradiotherapyCystectomy03 medical and health scienceschemistry.chemical_compoundTransitional cell carcinomacystectomy0302 clinical medicineInternal medicinemedicineBladder cancerPerformance statusbusiness.industrymedicine.diseaseCarboplatinGemcitabine3. Good healthRegimenTransitional cell carcinomaOncologychemistrycomparative effectiveness research030220 oncology & carcinogenesisbusinessChemoradiotherapymedicine.drugBladder Cancer
researchProduct